Capítulo · Oncologia e Hematologia - Ed. XIX
The Role of the Integrated Stress Response (ISR) in Breast Cancer Therapy Resistance
- ISBN 978-65-6029-354-0
- DOI https://doi.org/10.59290/2013200950
- Ano 2026
- Palavras-chave Integrated Stress Response; Breast Cancer; Therapy Resistance
Resumo
The Role of the Integrated Stress Response (ISR) in Breast Cancer Therapy Resistance
The integrated stress response (ISR) is a conserved and adaptive signaling pathway activated in eukaryotic cells in response to various physiological alterations and pathological conditions. It enables cells to detect and integrate diverse stress signals through regulation of eukaryotic initiation factor 2 alpha (eIF2α). Phosphorylation of eIF2α is a central event in ISR activation and results in a global reduction in protein synthesis, thereby limiting the accumulation of misfolded proteins during stress. At the same time, this phosphorylation selectively enhances the translation of specific stress-related genes, particularly activating transcription factor 4 (ATF4), which promotes the expression of genes involved in alleviating proteotoxic stress, supporting cell survival, and facilitating recovery. However, prolonged or excessive activation of the ISR can shift the cellular response from adaptation to programmed cell death. This dual function highlights the ISR as a finely regulated system that balances survival and acell death depending on context and magnitude of the stress. The ISR has emerged as a critical pathway in tumor development, progression, and response to therapy. Tumor cells often experience high levels of intrinsic stress due to rapid proliferation, increased metabolic demands, and elevated protein synthesis. These conditions place significant pressure on the endoplasmic reticulum (ER) and increase oxidative stress. Oncogene-driven translational activity, along with microenvironmental challenges such as hypoxia and nutrient deprivation, further intensifies cellular stress. Moreover, exposure to anti-cancer treatments, including chemotherapy and targeted therapies, can activate the ISR. In breast cancer, sustained or dysregulated ISR signaling has been associated with enhanced survival under treatment-induced stress, thereby limiting treatment effectiveness. Given its role in promoting cancer cell adaptation and